Carpe Diem

Tag: Biotech

Moderna and Merck cancer vaccine illustration showing personalized mRNA therapy, a 42% risk reduction and 500+ vaccine candidates.

Cancer Vaccines: Moderna & Merck's Breakthrough Opens the Door to 500+ Candidates 🧬💉

🧬💉 Moderna ($MRNA) and Merck ($MRK) have achieved a landmark Phase III success in personalized cancer vaccination, reducing the relative risk of melanoma recurrence or death by 42% when combined with Keytruda. But here's the truly extraordinary part: more than 500 cancer vaccine candidates are already in development worldwide. Many questions remain, and nothing is guaranteed. Yet the scientific possibilities have rarely looked more exciting. Carpe Diem! ❤️

Read entire article